N.M. Admin. Code § 16.19.20.65
Current through Register Vol. 35, No. 21, November 5, 2024
Section 16.19.20.65 - SCHEDULE IA. Section 30-31-6 NMSA 1978, schedule I shall consist of the following drugs and other substances, by whatever name, common or usual name, chemical name or brand name designated, listed in this section; OPIOIDS, unless specifically exempt or unless listed in another schedule, any of the following opioids, including its isomers, esters, ethers, salts and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation.(6) Alpha-methyl fentanyl;(17) Dimethylthiambutene;(21) Dimethylthiambutene;(22) Dioxaphetyl Butyrate;(24) Ethylmethylthiambutene;(32) Levophenacylmorphan;(49) U-48800; (2-(2,4-dichlorophenyl)-N-((1S,2S)-2-(dimethylamino)cyclohexyl)-N-methylacetamide, monohydrochloride;(50) U-49900; (trans-3,4-dichloro-N--N-methyl-benzamide;(51) Beta-Hydroxy-3-Methylfentanyl;(52) 3-Methylthiofentanyl;(53) Acetyl-Alpha-Methyl fentanyl;(54) Alpha-Methylthiofentanyl;(55) Beta-hydroxfentanyl;(56) Para-Fluoro fentanyl;(60) Betahydroxythiofentanyl;(62) AH-7921; (3,4-dichloro-N-benzamide);(63) U47700; (trans-3,4-dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide);(64) MT-45; (1-(4-Nitrophenylethyl)piperidylidene-2-(4-chlorophenyl)sulfonamide);(65) W-15; (4-chloro-N--benzenesulfonamide);(66) W-18; (1-(4-Nitrophenylethyl)piperidylidene-2-(4-chlorophenyl)sulfonamide);(67) U-50488; (2-(3,4-dichlorophenyl)-N-methyl-N-acetamide);(68) U50488H; ((-)(trans)-3,4-dichloro-N-methyl-N-benzeneacetamide).(69) Fentanyl-related substances, their isomers, esters, ethers, salts, and salts of isomers, esters and ethers. Fentanyl-related substance means any substance, unless specifically exempted or unless listed in another schedule, that is structurally related to fentanyl by one or more of the following modifications: (a) replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle;(b) substitution in or on the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino or nitro groups;(c) substitution in or on the piperidine ring with alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino or nitro groups;(d) replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle; or(e) replacement of the N-propionyl group by another acyl group; or(f) any combination of the above substances include, but are not limited to, the following substances: (reserved)(72) 4-methoxybutyrfentanyl;(73) Fluorobutyrfentanyl;(75) FIBF; (Para Fluoro Isobutyryl Fentanyl);(76) Cyclopropyl fentanyl;(77) Thiofuranyl fentanyl (Thiophene fentanyl);(78) 3-methylfentanyl (N-3-methyl-1-(2-phenyl-ethyl)-4-Piperidyl)-N-phenylpropanamide, its optical and geometric isomers, salts and salts of isomers;(79) crotonyl fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2- enamide);(80) valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide);(81) N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propionamide (2'-fluoro ortho-fluorofentanyl; 2'-fluoro 2-fluorofentanyl);(82) N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide (4'-methyl acetyl fentanyl);(83) beta-phenyl fentanyl or N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide ([BETA]'-phenyl fentanyl; beta'-Phenyl fentanyl; 3-phenylpropanoyl fentanyl);(84) beta-methyl fentanyl or N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide ([BETA]-methyl fentanyl);(85) N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide (ortho-fluorobutyryl fentanyl; 2-fluorobutyryl fentanyl);(86) (N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide (ortho-methyl acetylfentanyl; 2-methyl acetylfentanyl);(87) 2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide (ortho-methyl methoxyacetylfentanyl; 2-methyl methoxyacetyl fentanyl);(88) N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (para-methylfentanyl; 4-methylfentanyl);(89) N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide (phenyl fentanyl; benzoyl fentanyl);(90) N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide (thiofuranyl fentanyl; 2-thiofuranyl fentanyl; thiophene fentanyl)(91) Ethyl (1-phenethylpiperidin-4- yl)(phenyl)carbamate (fentanyl carbamate);(92) N-(2-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)acrylamide (ortho-fluoroacryl fentanyl);(93) N-(2-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)isobutyramide (ortho-fluoroisobutyryl fentanyl);(94) N-(4-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)furan-2- carboxamide (para-fluoro furanyl fentanyl);(95) cyclopentyl fentanyl;(96) isobutyryl fentanyl;(97)para-chloroisobutyryl fentanyl;(98)para-methoxybutyryl fentanyl;(99)para-fluorobutyryl fentanyl;(101) Ortho-Fluorofentanyl;(102) Tetrahydrofuranyl Fentanyl;(103) Methoxyacetyl Fentanyl;(104) 4-Fluoroisobutyryl Fentanyl;(105) Para-Fluorofentany;l(106) Butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1Hbenzimidazol-1-yl)-N,N-diethylethan-1- amine);(107) Etodesnitazene; etazene (2-(2-(4-ethoxybenzyl)-1Hbenzimidazol-1-yl)-N,N-diethylethan-1- amine);(108) Metonitazene (N, N -diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1 H -benzimidazol-1-yl)ethan-1-amine);(109) Flunitazene (N, N -diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1 H -benzimidazol-1-yl)ethan-1-amine);(110) Metodesnitazene (N,6 N -diethyl-2-(2-(4-methoxybenzyl)-1 H -benzimidazol-1-yl)ethan-1-amine);(111) Protonitazene (N, N -diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1 H -benzimidazol-1-yl)ethan-1-amine);(112) Brorphine (1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2 H -benzoimidazol-2-one);(113) Zipeprol (1-methoxy-3--1- phenylpropan-2-ol).B.OPIUM DERIVATIVES: Unless specifically exempt or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation.(2) Acetyl dihydrocodeine;(4) Codeine methylbromide;(13) Methyldihydromorphine;(14) Morphine methylbromide;(15) Morphine methylsulfonate;(24) 6AM; (6-acetylmorphine).C.STIMULANTS: Unless specifically exempted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers.(3) cis-4-methylaminorex;(4) N, N-dimethylamphetamine;(5) (BZP), 1-benzylpiperazine; N-benzylpiperazine;(6) (DCPP); 2,3-dichlorophenylpiperazine;(7) (DBZP); dibenzylpiperazine;(8) (MBZP); methylbenzylpiperazine;(9) (mCPP); meta-chlorophenylpiperazine;(10) (MDBZP);methylenedioxybenzylpiperazine;(11) (meOPP); para-methoxyphenylpiperazine;(12) (pCPP); para-chlorophenylpiperazine;(13) (pFPP); para-fluorophenylpiperazine;(14) (2-DPMP), desoxypipradrol; 2-diphenylmethylpiperidine;(15) D2PM, diphenylprolinol; diphenyl-2-pyrrolidinemethanol;(16) HDMP-28; methylnaphthidate;(17) Nocaine, (+)-CPCA; 3[ALPHA]-carbomethoxy-4[BETA]-(4-chlorophenyl)-N-methylpiperidine;(18) BTQ or butyltolylquinuclidine; (2-Butyl-3-(p-tolyl)quinuclidine;(19) Methiopropamine; (N-methyl-1- (thiophen-2-yl)propan-2-amine);(20) Mesocarb; (N-phenyl-N' -(3-(1-phenylpropan-2-yl)-1,2,3- oxadiazol-3-ium-5-yl)carbamimidate);(21) Amineptine (7- cyclohepten-5- yl)amino]heptanoic acid);(22) 4,4'-Dimethylaminorex (4,4'-DMAR; 4,5-dihydro-4- methyl-5-(4-methylphenyl)-2-oxazolamine; 4-methyl-5- (4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine).D.DEPRESSANTS: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation: (4) Gamma hydroxybutyric acid and any chemical compound that is metabolically converted to GHB;(5) Gamma butyrolactone and any chemical compound that is metabolically converted to GHB;(6) 1-4 butane diol and any chemical compound that is metabolically converted to GHB(7) GHV or 4-methyl-GHB; [GAMMA]-hydroxyvaleric acid;(8) GVL; [GAMMA]-valerolactone;(9) MMQ; methylmethaqualone;E.HALLUCINOGENIC SUBSTANCES: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation, which contains any quantity of the following hallucinogenic substances, or which contains any of its salts, isomers, and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation (for purpose of this sub-section only, the term "isomers" includes the optical, positional, and geometric isomers). (1) 3,4 -methylenedioxy amphetamine;(2) 5 - methoxy - 3,4-methylenedioxy amphetamine;(3) 3,4,5 -trimethoxy amphetamine;(5) DET; (Diethyltryptamine);(6) DMT; (Dimethyltryptamine);(7) DOM or STP; (4-methyl-2,5-dimethoxy amphetamine);(9) Lysergic acid diethylamide;(12) N-ethyl-3-piperidyl benzilate;(13) N-methyl-3-piperidyl benzilate;(16) Parahexyl (synthetic analog of delta-9-tetrahydrocannabinol);(17) 2, 5 -dimethoxyamphetamine; 2, 5-DMA;(18) 4-bromo-2, 5-dimethoxy-amphetamine; 2, 5-DMA;(19) PMA; 4-methoxyamphetamine;(20) PCE; (Ethylamine N-ethyl-1-phenylcyclohexylamine);(21) Pyrrolidine 1-(1-phenylcyclohexyl)-pyrrolidine (PCPy), (PHP) analog of the drug phencyclidine;(22) Thiophene (analog of phencyclidine) TCP or TPCP;(23) Alpha-ethyltryptamine;(24) 2, 5-dimethoxy-4-ethylamphet-amine;(26) 2C-T-7; (2,5-dimethoxy-4-(n)-propylthiophenethylamine);(27) AMT; (Alpha-methyltryptamine);(28) 5-MeO-DIPT; (5-methoxy-N,N-diisopropyltryptamine);(29) 25B-NBOMe; (2-(4-bromo-2.5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine);(30) 25C-NBOMe; (2-(4-chloro-2.5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine);(31) 25I-NBOMe; (2-(4-iodo-2.5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine).(32) Synthetic cannabinoids: Unless specifically exempted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following synthetic cannabinoids which demonstrates binding activity to the cannabinoid receptor or analogs or homologs with binding activity. Substances include but are not limited to: (a) CP 55,244 ((hydroxymethyl)-4- 1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-2-ol);(b) CP 55,940 (5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)phenol);(c) JWH-081 (1-pentyl-3-indole);(d) JWH-122 (1-pentyl-3-(4-methyl-1-naphthoyl)indole);(e) JWH-133 3-(1,1-dimethylbutyl)-6a,7,10,10a-tetrahydro -6,6,9-trimethyl-6H dibenzopyran;(f) JWH 203 1-pentyl-3-(2-chlorophenylacetyl)indole);(g) JWH 210 4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone;(h) AM-694 (1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole);(i) AM-1221 (1-(N-methylpiperdin-2-yl)methyl-2-methyl-3-(1-naphthoyl)-6-nitroindole;(j) AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole);(k) RCS-4 or SR-19 (1-pentyl-3-indole);(l) RCS-8 or SR-18 (1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole);(m) JWH-210 (1-pentyl-3-(4-ethylnaphthoyl)indole);(n) WIN-49,098 (Pravadoline) (4-methoxyphenyl)-methanone;(o) WIN-55,212-2 (2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo-1,4-benzooxazin6- yl)-1-naphthalenylmethanone);(p) any of the following synthetic cannabinoids, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation; (i) naphthoylindoles: any compound containing a 3-(1- naphthoyl) indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, JWH-210, JWH-398 and AM-2201;(ii) naphthylmethylindoles: any compound containing a1Hindol- 3-yl-(1-naphthyl) methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-175, JWH-184, and JWH-199;(iii) naphthoylpyrroles: any compound containing a 3-(1- naphthoyl) pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-307;(iv) naphthylmethylindenes: any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-176;(v) phenylacetylindoles: any compound containing a 3- phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent including, but not limited to, JWH-203, JWH-250, JWH-251, and RCS-8;(vi) cyclohexylphenols: any compound containing a 2-(3- hydroxycyclohexyl) phenol structure with substitution at the 5- position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not substituted in the cyclohexyl ring to any extent including, but not limited to, Cannabicyclohexanol (CP 47,497 C8 homologue), CP 47,497 and CP 55,490;(vii) benzoylindoles: any compound containing a 3-(benzoyl) OTS-3833.4 indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4- morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent including, but not limited to, AM-694, Pravadoline (WIN 48,098), RCS-4, and AM-1241;(q) UR-144 1-(pentyl-1H-indol-3-yl) (2,2,3,3-tetramethylcyclopropyl) methanone;(r) XLR11 1-(5-fluoro-pentyl)-1H-indol-3-yl(2,2,3,3-tetramethylcyclopropyl)methanone;(s) AKB48 N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide;(t) QUPIC; Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate;(u) 5-fluoro-PB22; 5F-PB22; Quinolin-8-yl 1-(5-fluropentyl-1H-indole-3-carboxylate;(v) AB-FUBINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-flurobenzyl)-1H-indazole-3-carboxamide;(w) ADB-PINACA; N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamine;(x) AB-CHMINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide;(y) AB-PINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide;(z) THJ-2201; (naphthalen-1-yl)methanone;(aa) FDU-PB-22 IUPAC: 1-Naphthyl 1-(4-fluorobenzyl)-1H-indole-3 carboxylate;(bb) 5-fluoro ABICA: N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide;(cc) FUB-144 or FUB-UR-144; (2,2,3,3-tetramethylcyclopropyl)methanone;(dd) MN-18; N-(1-Naphthyl)-1-pentyl-1H-indazole-3-carboxamide;(ee) FUB-PB-22; Quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate;(ff) ADB-CHMINACA (N--1-(cyclohexylmethyl)-1H-indazole-3-carboxamide);(gg) AMB-FUBINACAor FUB-AMB (methyl(1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate);(hh) 5-fluoro-AMB (N-carbonyl]-L-valine, methyl ester);(ii) 5-fluoro-ADB (N-carbonyl]-3-methyl-D-valine, methyl ester);(jj) Bk-DMBDB or dibutylone; 1-(Benzo[1,3]dioxol-5-yl)-2-(dimethylamino)butan-1-one;(kk) MMB-FUBINACA; methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate;(ll) MDMB-CHMICA; methyl (S)-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate;(mm) NM2201; Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate;(nn) 5-Fluoro-AKB48 or 5F-APINACA; N-((3s,5s,7s)-adamanta-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide;(oo) 5-Fluoro-ADB; Methyl(S)-2--3,3-dimethylbutanoate;(pp) 5-Fluoro-AMB; N-carbonyl]-L-valine,methyl ester;(qq) MAB-CHMINACA; N--1-(cycohexylmethyl)-1H-indazole-3-carboxamide;(rr) SDB-006; N-benxyl-1-pentyl-1H-indole-3-carboxamide;(ss) Cumyl-PINACA; 1-pentyl-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide;(tt) Cumyl-PICA; 1-pentyl-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide;(uu) 5F-CUMYL-PINACA; SGT-25; 1-(5-Fluoropentyl)-N-(2-phenylpropan-2- yl)-1H-indazole-3-carboxamide;(vv) 5F-EDMB-PINACA; Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)- 3,3-dimethylbutanoate;(ww) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate;(xx)N -(Adamantan-1-yl)-1-(4-fluorobenzyl)-1 H -indazole-3-carboxamide (FUB-AKB48; FUB-APINACA; AKB48 N -(4-fluorobenzyl));(yy) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1 H-indazole-3-carboxamide (4-CN-CUMYL-BUTINACA, 4-cyano-CUMYL-BUTINACA; 4-CN-CUMYL BINACA, CUMYL-4CN-BINACA, or SGT-78);(zz) methyl 2-(1-(cyclohexylmethyl)-1 H-indole-3-carboxamido)-3-methylbutanoate (MMB-CHMICA or AMB-CHMICA);(aaa) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1 H-pyrrolopyridine-3-carboxamide (5F-CUMYL-P7AICA)(33) Substances determined by the board to have the pharmacological effect of the substance, the risk to the public health by abuse of the substance and the potential of the substance to produce psychic or physiological dependence liability is similar to the substances described in Paragraph (1) or (2) of 30-31-23C NMSA 1978. Substances include but are not limited to: (b) Salvinorin A (methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-2H-benzoisochromene-7-carboxylate);(34) (4-MEC); 4-methyl-ethylcathinone;(35) (4-EMC); 4-ethyl-methcathinone;(36) Ethcathinone; 2-ethylamino-1-phenyl-propan-1-one;(37) Ethylone; 3',4'-methylenedioxyethcathinone;(38) Bk-MBDB, butylone; beta-keto-N-methyl-3,4-benzodioxyolybutanamine;(39) (NRG-1), naphyrone; naphthylpyrovalerone; (40) Metamfepramone; N,N-dimethylcathinone;(41) Alpha-PPP; alpha-pyrrolidinopropiophenone;(42) ([ALPHA]-PBP); alpha-pyrrolidinobutiophenone;(43) (MOPPP); 4'-methoxy-alpha-pyrrolidinopropiophenone;(44) (M[ALPHA]PPP); 4'-methyl-[ALPHA]-pyrrolidinopropiophenone;(45) (MDPPP); 3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone;(46) (MDPBP); 3',4'-methylenedioxy-alpha-pyrrolidinobutiophenone;(47) (MPBP); 4'-methyl-[ALPHA]-pyrrolidinobutiophenone; (48) Alpha-PVP; alpha-pyrrolidinovalerophenone;(49) (MDAI); 5,6-methylenedioxy-2-aminoindane; (50) Buphedrone; alpha-methylamino-butyrophenone;(51) Eutylone; beta-keto-ethylbenzodioxolylbutanamine;(52) beta-keto-ethylbenzodioxolylpentanamine;(53) beta-keto-methylbenzodioxolylpentanamine (pentylone);(54) 4-Bromo-2,5-dimethoxyphenethylamine (2c-B, Nexus);(55) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hydroxy-alphamethyl-3,4(methylenedioxy)-phenethylamine, and N-hydroxy MDA;(56) 5-methoxy-N,N-dimethyltryptamine (5-methoxy-3-indole; 5-MeO-DMT;(57) Mephedrone; 4-methylmethcathinone;(58) (MDPV); 3,4-methylenedioxypyrovalerone; (59) (2C-E); 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine;(60) (2C-D); 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine;(61) (2C-T-2); 2-ethanamine;(62) (2C-T4); 2-ethanamine;(63) (2C-H); 2-(2,5-Dimethoxyphenyl)ethanamine;(64) (2C-N); 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine;(65) (2C-P); 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine;(66) Methylone; 3,4-Methylenedioxy-N-methylcathinone;(67) Aminorex (2-amino-5-phenyl-2-oxazoline);(69) 4-FMC or flephedrone; 4-fluro-N-methylcathinone;(70) (3-FMC); 3-fluro-N-methylcathinone;(71) (3-MMC); 3-methylmethcathinone;(72) (3,4 DMMC); 3,4-Dimethylmethcathinone;(73) (3-MEC); 3-Methyl-N-ethylcathinone;(74) 4-methylbuphedrone or 4-MeBP; 2-methylamino-1-(4-methylphenyl)butan-1-one(75) (4 MTA); 4-methylthioamphetamine;(76) (5-Me MDA); 5-methyl-3,4-methylenedioxyamphetamine;(77) (6-APB); 6-benzofuran;(78) (PMA); 4-methoxyamphetamine;(79) (2C-B); 2,5-dimethoxy-4-bromophenethylamine;(80) (2C-C); 2,5-dimethoxy-4-chlorophenethylamine;(81) (2C-D); 4-methyl-2,5-dimethoxyphenethylamine;(82) (2C-E, aquarust, cindy); 2,5-dimethoxy-4-ethylphenethylamine;(83) (2C-G); 3,4-dimethyl-2,5-dimethoxyphenethylamine;(84) (2C-I); 2,5-dimethoxy-4-iodophenethylamine;(85) (2C-T21); 2-ethanamine;(86) (2C-B-FLY); 2-(8-bromo-2,3,6,7-tetrahydrofuro [1]benzofuran-4-yl)ethanamine;(87) Bromo-DragonFLY or 3C-Bromo-Dragonfly or DOB-Dragonfly; 1-(4-Bromofuro[1]benzofuran-8-yl)propan-2-amine;(88) (DOB); 2,5-Dimethoxy-4-bromoamphetamine;(89) (DOC); 2,5-Dimethoxy-4-chloroamphetamine;(90) (DOM); 2,5-Dimethoxy-4-methylamphetamine;(91) (TMA2); 2,4,5-trimethoxyamphetamine;(92) (TMA6); 2,4,6-trimethoxyamphetamine;(93) (MDAT); 6,7-methylenedioxy-2-aminotetralin; (94) (4-acetoxy DiPT, ipracetin); 4-acetoxy-N,N-diisopropyltryptamine;(95) (4-acetoxy DMT, psilacetin;) O-Acetylpsilocin;(96) 4-HO MET, metocin; 4-hydroxy-N-methyl-N-ethyltryptamine;(97) 4-HO MiPT, hats; 4-hydroxy-N-methyl-N-isopropyltryptamine;(98) 5-MeO-aMT, Alpha-O; 5-methoxy-[ALPHA]-methyltryptamine;(99) (5-MeO-MiPT); N--N-methylpropan-2-amine;(100) (DiPT); N,N-diisopropyltryptamine;(101) (DPT); dipropyltryptamine;(102) (5-MeO-DALT); N,N-diallyl-5-methoxytryptamine;(103) (3-MeO PCP); 3-methoxyphencyclidine;(104) (4-MeO PCP); 4-methoxyphencyclidine;(105) (MK-801); dizocilpine;(106) (PCE, perchloroethylene, perchloroethene), Perc; tetrachloroethylene;(107) (PCE, perchloroethylene, perchloroethene), Perc; tetrachloroethylene;(108) (PCPr); phencyclamine, N-(1-phenylcyclohexyl)propanamine; (109) (Tenocyclidine); 1-(1-(2-thienyl)cyclohexyl)piperidine(110) (3-MeO PCE); 3-methoxyeticyclidine, N-ethyl-1-(3-methoxyphenyl)cyclohexanamine;(111) (ETH-LAD); 6-ethyl-6-nor-lysergic acid diethylamide; (112) (AL-LAD); 6-allyl-6-nor-LSD;(113) (PRO-LAD); 10-didehydroergoline-8-carboxamide;(114) ((1-(1,3-benzodioxol-5-yl)-2-(ethylamino)pentan-1-one, N- ethylpentylone);(115) (MPHP), 4´-methyl-alpha-pyrrolidinohexiophenone; (116) 4'-chloro-alpha-pyrrolidinovalerophenone (4-chloro-[ALPHA]-PVP; 4'-chloro-[ALPHA]-pyrrolidinopentiophenone);(117) 4-methyl-alpha-ethylaminopentiophenone (4-MEAP; 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one);(118) alpha-pyrrolidinoheptaphenone (PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one);(119) alpha-pyrrolidinohexanophenone ([ALPHA]-PHP; [ALPHA]-pyrrolidinohexanophenone; 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one);(120) N-ethylhexedrone ([ALPHA]-ethylaminohexanophenone; 2-(ethylamino)-1- phenylhexan-1-one);(121) Methoxetamine; 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one; 2-(3-methoxyphenyl)-2-(N-ethylamino)cyclohexanone; MXE).F. Any material, compound, mixture or preparation which contains any quantity of the following substances. (1) 3, 4-methylenedioxymethamphetamine (MDMA), its optical, positional and geometric isomers, salts and salts of isomers;(2) (MPPP); 1-methyl-4-phenyl-4-proprionoxypiperidine its optical isomers, salts, and salts of isomers; (3) 1-(-2-phenylethyl)-4-phenyl-4-acetoxy piperidine (PEPAP), its optical isomers, salts and salts of isomers;(7) para- Methoxymethamphetamine (PMMA)N.M. Admin. Code § 16.19.20.65
16.19.20.65 NMAC - Rp 16 NMAC 19.20.28, 07-15-02; A, 06-30-05; A, 01-15-08; A, 05-14-10; A, 11-27-11; A, 06-15-12; A, 08-31-12; A, 12-19-13; A, 06-28-14, Amended by New Mexico Register, Volume XXVI, Issue 22, November 30, 2015, eff. 12/13/2015, Amended by New Mexico Register, Volume XXVII, Issue 19, October 14, 2016, eff. 10/16/2016, Amended by New Mexico Register, Volume XXVIII, Issue 05, March 14, 2017, eff. 3/29/2017, Adopted by New Mexico Register, Volume XXIX, Issue 12, June 26, 2018, eff. 6/26/2018, Amended by New Mexico Register, Volume XXX, Issue 23, December 17, 2019, eff. 12/17/2019, Amended by New Mexico Register, Volume XXXII, Issue 17, September 14, 2021, eff. 9/14/2021, Amended by New Mexico Register, Volume XXXIV, Issue 11, June 13, 2023, eff. 6/13/2023